Highlights in Acute Lymphoblastic Leukemia From ASH 2021

Mark R. Litzow, MD


January 10, 2022

Dr Mark R. Litzow, from the Mayo Clinic, highlights four important acute lymphoblastic leukemia (ALL) studies presented at this year's American Society of Hematology annual meeting.

First, Dr Litzow covers two trials that tested the viability of pediatric-inspired regimens in adult patients with ALL. GRAALL-2005, he explains, is the first trial to evaluate the prognostic impact of central nervous system (CNS) involvement in adults with ALL using a pediatric protocol. He then discusses GMALL-08/2013, a risk-adapted and minimal residual disease (MRD)-stratified trial of patients with newly diagnosed ALL or lymphoblastic lymphoma. GMALL confirmed that a pediatric-intensive regimen shows promising benefits for older adults when used in combination with targeted therapy and stem cell transplantation.

Next, Dr Litzow presents the first promising results from the EWALL-INO study of older patients with CD22+ Philadelphia chromosome–negative B-cell precursor (Ph+) ALL. This phase 2 multicenter study found the safety and efficacy of a combination therapy of reduced fractionated inotuzumab dosing and low-intensity chemotherapy to be an active and well-tolerated frontline therapy.

Finally, he reports on 2298, a late-breaking abstract of updated trial results that may offer an effective transplant-sparing regimen for adult patients with newly diagnosed, relapsed/refractory, or chronic myeloid leukemia Ph+ ALL.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.